<< Read Full Article
<< Read Full Article
Updated from 4:51 p.m. EDT
A panel of experts on Thursday recommended to further limit the use of anemia drugs sold by Amgen (AMGN Quote) and Johnson & Johnson (JNJ Quote) to treat cancer patients.
The panel did, however, decide against completely restricting the drugs' use in cancer patients, sending shares of Amgen up nearly 5%. The company had the most risk from the panel meeting, since its drug under review, Aranesp, is its biggest seller.
The U.S. Food and Drug Administration convened the advisory panel to review new clinical data linking anemia drugs such as Aranesp and Johnson & Johnson's Procrit to worsening cancer or increased risk of death. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,405.83 | 1,102.35 | 2,190.86 | 34.82 |
Oil *
71.98
|
|
UP
68.78
|
UP
6.41
|
UP
7.13
|
UP
0.59
|
10 Yr
3.48%
SPDR Gold
110.82
|
|
+0.67%
|
+0.58%
|
+0.33%
|
+1.72%
|
Data delayed 20 minutes |
Connect with TheStreet